1. Market Research
  2. > Healthcare
  3. > Medical Facility Market Trends
  4. > Bispecific Antibodies: Clinical Trial Tracker

Bispecific Antibodies: Clinical Trial Tracker

  • February 2014
  • -
  • Roots Analysis Private Ltd.

INTRODUCTION

The primary objective of this report is to capture details on the various clinical and preclinical trials which are currently underway in the field of Bispecific Antibody Therapeutics. We have identified a number of such trials which are taking place for a variety of indications across multiple geographies.

For each specific trial, we have provided the following information:

1. Trial Objective
2. Manufacturer / Licensee
3. Technology
4. Target Antigen
5. Indication
6. Sponsor / Collaborator
7 Trial Phase
8. Trial Status
9. Start Date
10. End Date
11. Enrolment
12. Age Group
13. Inclusion Criteria
14. Exclusion Criteria
15. Study Design
16. Primary Endpoint
17. Secondary Endpoint
18. Treatment Arms
19. Route of Administration
20. Location(s)
21. Trial Results (if known)

The above information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space.

In addition to the clinical trial details, the report also provides the following:
- Detailed forecasts of the bispecific antibody market over the course of next ten years. Owing to the niche nature of this market, we have presented three scenarios to add robustness to our market forecast. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.
- Industry SWOT analysis summarising the challenges as well as opportunities in the market for different stakeholders.

RESEARCH METHODOLOGY

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Other analysts’ opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Table Of Contents

Bispecific Antibodies: Clinical Trial Tracker
Introduction and Pipeline Details
1. Market Overview
2. Dashboard: Pipeline Analysis
3. Molecules in Clinical Development: Trial Details
4. Molecules in Preclinical Development: Trial Details
5. Inclusion / Exclusion Criteria

Market Forecast, 2013 - 2023
6. Market Forecast: Assumptions
7. Market Forecast: Details
8. Comparative Forecast Scenarios

Industry Analysis
9. Industry SWOT Analysis

LIST OF FIGURES

Pipeline Details
Figure 1: Bispecific Antibodies in Clinical Development: Distribution by Companies
Figure 2: Bispecific Antibodies in Clinical Development: Distribution by Highest Phase of Development
Figure 3: Bispecific Antibodies in Clinical Development: Distribution by Type of Bispecific System
Figure 4: Bispecific Antibodies in Clinical Development: Distribution by Indication
Figure 5: Bispecific Antibodies Clinical Trials: Distribution by Trial Phase and Status (Matrix View)
Figure 6: Bispecific Antibodies Clinical Trials: Distribution by Trial Status
Figure 7: Bispecific Antibodies Clinical Trials: Distribution by Trial Phase
Figure 8: Bispecific Antibodies Clinical Trials: Distribution by Indication
Figure 9: Bispecific Antibodies Clinical Trials: Distribution by Sponsor Type
Figure 10: Bispecific Antibodies Clinical Trials: Distribution by Region
Figure 11: Bispecific Antibodies Clinical Trials: Distribution by Molecules and Countries (Matrix View)
Figure 12: Bispecific Antibodies Clinical Trials: Distribution by G7 Countries
Figure 13: Bispecific Antibodies Clinical Trials: Distribution by EU5 Countries
Figure 14: Bispecific Antibodies in Preclinical Development: Distribution by Indication

Market Forecast
Figure 15: Bispecific Antibody Therapeutics Market Forecast, Base Scenario (USD MM)
Figure 16: Bispecific Antibody Therapeutics Market Forecast, Scenario Comparison (USD MM)

LIST OF TABLES

Pipeline Details
Table 1: Molecules in Clinical Development: Pipeline Details
Table 2: Molecules in Preclinical Development: Pipeline Details

Market Forecast
Table 3: Expected Launch Year of Bispecific Antibodies in Clinical Development

Industry Analysis
Table 4: SWOT Analysis

Companies Mentioned

1. AbbVie
2. Ablynx
3. Adimab
4. Affimed Therapeutics
5. AGO Study Group
6. Allergan
7. Alligator Bioscience
8. Allozyne
9. Ambrx
10. Amgen
11. Amphivena Therapeutics Inc.
12. Baliopharm
13. Barbara Ann Karmanos Cancer Institute
14. Bayer
15. Beijing ABT Genetic Engineering Technology Co.
16. Biogen Idec
17. Bioline Rx
18. Biotecnol
19. Boehringer Ingelheim
20. Celgene
21. Centre Rene Gauducheau
22. Chiome Bioscience
23. Chugai
24. Dutalys
25. Eddingpharm
26. Eli Lilly
27. Emergent Biosolutions
28. Fabion Pharmaceuticals
29. Fresenius Biotech
30. F-star
31. Ganymed Pharmaceuticals
32. Garden State Cancer Center at the Center for Molecular Medicine and Immunology
33. Genentech
34. Genmab
35. Gilead
36. Grupo Español de Investigación en Cáncer de Ovario; Neovii Biotech
37. GSK
38. Gustave Roussy, Cancer Campus, Grand Paris
39. Ho Research Consortium
40. ImClone System
41. Immunomedics
42. Innovent Biologics Inc.
43. Institut National de la Sante Et de la Recherche Medicale, France
44. International Joint Cancer Institute, the Second Military Medical University
45. Janssen Biotech
46. Jsehouli
47. Krankenhaus Nordwest
48. Kyowa Hakko Kirin
49. MacroGenics
50. Masonic Cancer Center, University of Minnesota
51. MediaPharma S.R.L
52. MedImmune
53. Memorial Sloan-Kettering Cancer Center
54. Merck
55. Merrimack Pharmaceuticals
56. Merus B.V.
57. Molecular Partners AG
58. Nantes University Hospital
59. National Cancer Institute
60. National Engineering Research Center for Antibody Medicine
61. NeoPharm
62. Neovii Biotech
63. Novartis
64. NovImmune
65. Numab
66. OncoMed Pharmaceuticals
67. Paktis Antibody Services GmbH
68. Pfizer
69. PharmAbcine
70. PLA General Hospital Cancer Center, Beijing
71. Protheragen
72. Radboud University
73. Regeneron Pharmaceuticals
74. Roche
75. Roger Williams Medical Center
76. Sanofi
77. School of Medicine, Shanghai Jiao Tong University
78. Sea Lane Biotechnologies
79. Servier
80. State Key Laboratory of Antibody Medicine and Targeted Therapy
81. Sutro Biopharm
82. Synergys Biotherapeutics Inc.
83. Synimmune GmbH
84. Technische Universität München
85. Trion Pharma
86. University Hospital Tuebingen
87. University Hospital Tuebingen
88. University Witten/Herdecke
89. Xencor
90. Zymeworks
91. Zyngenia

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

Global Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 21100
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. Highlights - Identifies and evaluates major business opportunities emerging in the tumor marker market during ...

2016 Competing in the Global Cancer Diagnostics Market

2016 Competing in the Global Cancer Diagnostics Market

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

This new VPGMarketResearch.com comprehensive seven-country study identifies and evaluates major business opportunities emerging in the cancer diagnostics market during the next five years; examines trends ...

Tumor Markers 2020: Reagents and Instrumentation--Supplier Shares and Strategies, Country Segment Forecasts, Emerging Opportunities

Tumor Markers 2020: Reagents and Instrumentation--Supplier Shares and Strategies, Country Segment Forecasts, Emerging Opportunities

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. Highlights - Identifies and evaluates major business opportunities emerging in the tumor marker market during ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.